Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports Fourth Quarter & Full-Year 2021 Financial Results and Provides Clinical Update. To view the full press release, visit our website: https://zcu.io/MuRI

Lexicon Voluntarily Withdraws Sotagliflozin New Drug Application and Plans Prompt Resubmission Targeted Early Q2 2022. To view the full press release, visit our website: https://zcu.io/LUST

Lexicon Pharmaceuticals to Host Fourth Quarter 2021 Financial Results Conference Call & Webcast on February 28, 2022. For more information, please visit our website: https://zcu.io/M4z0

We presented yesterday at . If you missed it, you can watch what we presented here: https://zcu.io/FYvV

Lexicon Pharmaceuticals Outlines Major Potential Value for 2022 at 40th Annual J.P. Morgan Healthcare Conference. To read the full press release, visit our website: https://zcu.io/4NyE

Lexicon Pharmaceuticals to Participate in the 40th Annual J.P. Morgan Healthcare Conference. To view the full press release, please visit our website: https://zcu.io/bg00

Lexicon Submits New Drug Application for Sotagliflozin for the Treatment of Heart Failure in Adults with Type 2 Diabetes. To read the full press release, visit our website: https://zcu.io/UJL4

“Proud of SOLOIST and SCORED mention by the AHA as one of the Top Heart Disease and Stroke Research Advances of 2021. Recognition from the scientific community continues to build for the unique and important agent studied” – Craig Granowitz, M.D., Ph.D.
To view the AHA press release, visit their website: https://zcu.io/KD3f

The holiday season is here! Lexicon celebrated with a virtual holiday event, Nailed It – Painting Edition, where employees completed a 16x20 canvas together followed by a friendly competition of who painted best. Oh what fun it is to see the creative & competitive drive in our teams!

Lexicon Pharmaceuticals’ chief medical officer, Craig Granowitz, will be participating in the 18th Global Cardiovascular Clinical Trialists Forum today. View information on the panel discussion and Q&A here: https://zcu.io/WD0O

Now Available On Demand - Lexicon Pharmaceuticals presents at the Piper Sandler 33rd Annual Healthcare Conference. To view the webcast: https://zcu.io/zEwD

Now Available On Demand - Lexicon Pharmaceuticals presents at the Jefferies London Healthcare Conference. To view the webcast: https://zcu.io/XWfH

That’s a wrap for this year’s virtual . Thank you for another great year! View more on Lexicon’s involvement here: https://zcu.io/BcGH

Lexicon Pharmaceuticals to Particpate in the Jefferies London Healthcare Conference & the Piper Sandler 33rd Annual Healthcare Conference. To read the full press release, visit our website: https://zcu.io/qE77

Dr. Deepak L. Bhatt, MD, MPH presented a new analysis of the cardiovascular effects of SGLT1/2 inhibition across the full range of kidney function at . View more: https://zcu.io/55ZY

Dr. Deepak L. Bhatt, MD, MPH presenting data now at . View more: https://zcu.io/dpEp

kicks off today! Hear the latest health news including Dr. Deepak L. Bhatt, MD, MPH presentation tomorrow at 8:24 am ET. https://zcu.io/xOoo

kicks off this Saturday! Don’t miss the latest news in the world of health. More from Lexicon and Dr. Deepak L. Bhatt, MD, MPH here: https://www.lexpharma.com/media-center/news/791-new-analysis-to-be-presented-at-the-american-heart-association-scientific-sessions-2021-evaluating-cardiovascular-benefits-across-baseline-kidney-function

We’re looking forward to participating in . Learn more about our involvement here: https://zcu.io/RbFb

Join us today at 4 pm CST, for the Third Quarter 2021 Financial Results Update webcast. Link to the webcast, can be found on our website: https://zcu.io/6reb

Lexicon Pharmaceuticals Reports Third Quarter 2021 Financial Results Update. For more information, please visit our website: https://zcu.io/3fKo

Lexicon Pharmaceuticals’ Chief Medical Officer, Craig Granowitz, among distinguished panelists for the 17th International Conference on Emerging Technologies for a Smarter World (CEWIT2021). For more information on attending, visit their website: https://zcu.io/F6Vo

Lexicon Pharmaceuticals to Host Third Quarter 2021 Financial Results Conference Call & Webcast on November 3, 2021. For more information, visit our website: https://zcu.io/Kp0F

American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) jointly issue their consensus report on the management of type 1 diabetes in adults. Co-published in Diabetes Care and Diabetologia. Read the entire report here: https://zcu.io/l2em
https://zcu.io/USQB

That’s a wrap for this year’s virtual EASD Annual Meeting 2021. Thank you for another great year!

Hear the latest science on the potential benefits of SGLT inhibitors in type 1 diabetes during the short oral discussion event B (Tuesday, September 28 at 1:15 pm CEST/7:15 am ET) :

Session 606: “Sodium-glucose cotransporter 2 inhibitors as adjunct therapy for type 1 diabetes and the benefit on cardiovascular and renal disease evaluated by Steno risk engines”

Looking forward to hearing the latest science on diabetes. Virtual EASD Annual Meeting 2021 kicks off this week starting today!

Tomorrow at 10:45 a.m. ET, Lexicon Pharmaceuticals will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit. Please visit our website for webcast information: https://www.lexpharma.com/events

Lexicon Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on September 21, 2021. To view the full press release, visit our website: https://www.lexpharma.com/media-center/news/787-lexicon-pharmaceuticals-to-present-at-the-oppenheimer-fall-healthcare-life-sciences-medtech-summit

That’s a wrap on 2021! View more on Lexicon’s involvement here: https://www.lexpharma.com/

2021 guidelines establish SGLT inhibitors as part of the standard of care in acute and chronic . See more: https://www.lexpharma.com/media-center/news/786-lexicon-welcomes-new-esc-heart-failure-treatment-guidelines-establishing-sglt-inhibitors-as-standard-of-care